New oral medication may become tool against malaria
Sotrastaurin targets a specific enzyme to halt deadly spread of disease
Genetic research into how malaria enters and infects the human body has paved the way for a new oral medication that can now stop the deadly mosquito-borne disease in its tracks. Sotrastaurin, a drug that's already in clinical trials for use against another condition, may now become the frontline in battling a disease that has long plagued developing nations.
In tracking the progression of the disease, researchers learned that the malaria-infected female Anopheles mosquito injects about 1,000 parasites into the human bloodstream.
The microorganisms quickly reproduce after each one enters a red blood cell.
"Each parasite divides from one into say 24 to 32 parasites in 48 hours. So you can imagine that an initial thousand parasites can grow very fast," Doron Greenbaum, a professor of pharmacology at the University of Pennsylvania says.
Greenbaum and his colleagues discovered that inside the red blood cells, the parasites utilize a series of proteins to reproduce.
After robbing the cells of their nutrient machinery, the newborn parasites burst through the cell walls and back into the blood stream. It is here that they infect new blood cells, producing millions more offspring. After a one to two-week incubation period, the parasitic infection causes the often fatal symptoms associated with malaria. These commonly include high fevers, chills and sweats.
The malaria pathogen targets a particular enzyme called PKC, which weakens the protein chain, dismantling the cells and causing them to collapse. Sotrastaurin blocks P. falciparum's interaction with PKC.
Without that interactionthe parasites can't reproduce. "They are sort of trapped inside the host cell and if they can't get out, they can't continue their lifecycle and within a couple of hours, they start to die," Greenbaum said.
Greenbaum's team tested the experimental drug, now in clinical trials to prevent organ rejection in transplant patients. It was found that the compound dramatically reduced the number of P. falciparum malaria parasites in infected laboratory mice.
Because sotrastaurin targets human cellular proteins, Greenbaum says P. falciparum can't develop resistance to the drug which has made quinine and artemisinin drugs to treat malaria less effective in recent years.
© 2013, Distributed by NEWS CONSORTIUM.
Pope Francis Prayer Intentions for December 2013
General Intention: Victimized Children. That children who are victims of abandonment or violence may find the love and protection they need.
Missionary Intention: Prepare the Savior's Coming. That Christians, enlightened by the Word incarnate, may prepare humanity for the Savior's coming.
Rate This Article
Leave a Comment
More Health News
- New hepatitis-C drug approved by FDA
- Donors from around the world say that an AIDS-free generation may be within sight
- Washington signing up more people for Medicaid than private plans
- Man documents ravages of diabetes to his feet as they decay within 10 DAYS
- Dementia epidemic only growing worse: 135 million sufferers could arrive by 2050
- Men are from Mars, Women from Venus? Their brains are certainly wired differently
- Drinking water from plastic cups, bottles may be causing migraine headaches
- Apocalypse imminent as bacteria evolve beyond antibiotics
- New injection gives arthritics new hope
- Fr. Paul Schenck: Finding Living Faith on Catechetical Sunday
- The Movie Yellow: Incest as 'Normal' and Cassavates's Slides Into the World of Woes
- The Chicago School Teachers Strike Reveals the Need For School Choice
- The Sexual Barbarians and the Dissolution of Culture
- The Happy Priest Challenges Us to Ask: Who is Jesus to Me?
- Michael Coren on Canadian Public Schools: Teachers, leave those kids alone
- We Cannot Ignore Our Consciences: Cardinal Dolan On Religious Liberty
- In the Face of Danger, Successor of Peter Travels to Lebanon as a Messenger of Peace
- Reflections on the Dignity and Vocation of Women: Who or What?